SD GENOMICS CO.; LTD.;SD GENOMICS CO., LTD.;에스디지노믹스 주식회사
发明人:
KIM JONG WON,김종원,PARK JONG HO,박종호,WOO YOUNG MIN,우영민,PARK IN HO,박인호,PARK KYUNG SUN,박경선
申请号：
KR1020180116279
公开号：
KR1020180109811A
申请日:
2018.09.28
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing or treating malignant tumor containing a formulation for inhibiting the expression of HMGCLL1 IS3； a pharmaceutical composition for preventing or treating malignant tumor which exhibits resistance to a tyrosine kinase inhibitor； a method for providing information for determining drug resistance of a malignant tumor individual by using the expression level of HMGCLL1 IS3； a composition and a kit for diagnosing drug resistance which are used for the same method； a method for providing information for determining the possibility of disease occurrence of a malignant tumor by using the expression level of HMGCLL1 IS3； a method for screening a malignant tumor treating agent by using the expression level of HMGCLL1 IS3； a method for providing information for making a prognosis of a malignant tumor by using the expression level of HMGCLL1 IS3； a composition and a kit for making a prognosis of a malignant tumor comprising a formulation capable of measuring the expression level of HMGCLL1 IS3； a method for providing information for determining drug resistance of a malignant tumor by using SNP； a composition and a kit for diagnosing drug resistance which are used for the same method； a method for providing information for determining the probability of disease occurrence of a malignant tumor by using SNP； a method for providing information for making a prognosis of a malignant tumor by using SNP； and a composition and a kit for making a prognosis of a malignant tumor which are used for the same method. When the method of the present invention is used, the level of drug resistance of a patient who suffers from chronic myelogenous leukemia and a malignant tumor can be predicted or diagnosed in an effective manner. Furthermore, the method of the present invention can be applied to effective drug treatment and drug development research.COPYRIGHT KIPO 2018본 발명은 HMGCLL1 IS3의 발현을 억제하는 제제를 포함하는 악성종양의 예방 또는 치료
